| Literature DB >> 19151961 |
M Alter1, M Wittmann, B Völker, A Kapp, T Werfel, R Gutzmer.
Abstract
Treatment of autoimmune bullous diseases, especially of the pemphigus diseases, regularly requires the use of immunosuppressive drugs, often with insufficient clinical benefit but considerable side effects. A variety of autoimmune diseases (such as rheumatoid arthritis, lupus erythematosus, pemphigus vulgaris) have been successfully treated with rituximab, a chimeric monoclonal antibody against CD20, leading to a transient depletion of B cells. We report on three patients with pemphigus foliaceus who responded to rituximab after failing multiple other immunosuppressive therapies. We also examine the controversial issue of continuation therapy with rituximab in detail.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19151961 DOI: 10.1007/s00105-008-1682-0
Source DB: PubMed Journal: Hautarzt ISSN: 0017-8470 Impact factor: 0.751